Mankind Pharma investor deck: FY26 revenue crosses ₹14.2k Cr, chronic share targeted at ~50% by FY30, 70% stake in Belgian CAR-T firm ACTx
FY26 revenue ₹14.2k+ Cr; Q2 FY27 value growth 15.7% and volume growth 6.2% vs IPM 5.2%.
By ScoutQuest · · 1 min read
- FY26 revenue
- ₹14.2k+ Cr in FY26 from ₹8.7k+ Cr in FY23
- Q2 FY27 growth
- Q2 FY27 value growth 15.7% and volume growth 6.2% vs IPM 5.2%
- Chronic share
- 39% in FY26 from 28% in FY18
- Period
- Q2 FY27
- Positioning
- Mankind describes itself as a domestic pharma company grown from small-town GPs to super-specialists, with ~75% in-house manufacturing, 32 facilities and #1 rank in gynaecology in India including BSV.
📈 Revenue reached ₹14.2k+ Cr in FY26 from ₹8.7k+ Cr in FY23. Mankind volume growth moved from -0.6% in FY24 to 6.2% in Q2 FY27, ahead of IPM at 5.2%, with value growth of 15.7% and productivity of ₹7.4 lakh per MR per month.
🌍 Chronic share of sales rose to 39% in FY26 from 28% in FY18; cardiac market share is 5.5% and anti-diabetic 4.5%. Brand families above ₹50 Cr grew from 36 in FY21 to 54 in FY26, led by Telmikind at ₹783 Cr.
🏭 Management states a path to ~50% chronic share by FY30E through new specialty divisions, insulin and inhaler franchises and scaling brands to ₹50 Cr, ₹100 Cr and ₹200 Cr. For BSV, the company says it will pursue high revenue growth, deeper Anti-D and infertility penetration and emerging-market expansion.
🏭 The presentation lists a 70% stake in Belgium's ACTx for €48 Mn, paid in tranches, with founders retaining 30%. It also says a Vadodara biologics plant is under way for FY27-28, and cites large-pharma in vivo CAR-T deals as validation.
Also from Mankind Pharma
Mankind Pharma's strong Q2 results won brokerage support, with Jefferies and Kotak retaining buy ratings
27 Oct 2026
Mankind Pharma shares jumped 9% after Q2 earnings beat driven by strong domestic pharma growth and margin expansion
27 Oct 2026
Mankind Pharma stock surged nearly 10% after a strong conference call following its results announced during market hours
27 Oct 2026
More numbers
- Revenue, FY26₹14.2k+ Cr
- Revenue, FY23₹8.7k+ Cr
- In-house manufacturing share, FY26~75%
- Mankind volume growth, Q2 FY276.2%
- Mankind value growth, Q2 FY2715.7%
- Chronic share of sales, FY2639%
- Chronic share target, FY30E~50%
- Telmikind sales, FY26₹783 Cr
- Brand families above ₹50 Cr, FY2654
- ACTx consideration€48 Mn
- Stake acquired in ACTx70%
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.